8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 20, 2026·SEC
Novavax, Inc.(NVAX)Earnings, Financials & Key Ratios
NVAX•NASDAQ
3.6× P/E·Price updated Jun 19, 2026
AboutNovavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.Show more
- Revenue$1.12B+64.7%
- EBITDA$591M+394.8%
- Net Income$440M+334.8%
- EPS (Diluted)2.54+306.5%
- Gross Margin93.67%+33.3%
- EBITDA Margin52.59%+279.0%
- Operating Margin50.14%+237.4%
- Net Margin39.19%+242.6%
NVAX Key Insights
Novavax, Inc. (NVAX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 118.8%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 13.7% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NVAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NVAX Price & Volume
Novavax, Inc. (NVAX) stock price & volume — 10-year historical chart
Loading chart...
NVAX Growth Metrics
Novavax, Inc. (NVAX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years40.97%
5 Years118.83%
3 Years-11.1%
TTM-52.48%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-118.35%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-122.64%
Return on Capital
10 Years-111.69%
5 Years-154.96%
3 Years-112.06%
Last Year100.35%
NVAX Recent Earnings
Novavax, Inc. (NVAX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.06+76.0%
$0.25
Rev
$140M+74.8%
$80M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.11+116.7%
$0.66
Rev
$147M+63.8%
$90M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.62+42.6%
$1.08
Rev
$70M-22.0%
$90M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.62+985.7%
$0.07
Rev
$239M+330.1%
$56M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.06vs $0.25+76.0% | $140Mvs $80M+74.8% |
| Q1 2026 | Feb 26, 2026 | $0.11vs $0.66+116.7% | $147Mvs $90M+63.8% |
| Q4 2025 | Nov 6, 2025 | $0.62vs $1.08+42.6% | $70Mvs $90M-22.0% |
| Q3 2025 | Aug 6, 2025 | $0.62vs $0.07+985.7% | $239Mvs $56M+330.1% |
Based on last 12 quarters of dataView full earnings history →
NVAX Peer Comparison
Novavax, Inc. (NVAX) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MRNA | 25.37B | 63.96 | -8.81 | -39.23% | -143.55% | -36.73% | 0.22 | |
 BNTX | 22.98B | 90.89 | -17.51 | 0.2% | -39.6% | -6.03% | 0.01 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 SNY | 102.35B | 42.38 | 18.14 | 5.49% | 16.72% | 10.78% | 0.30 | |
 GSK | 101.9B | 50.67 | 6.86 | 4.11% | 19.19% | 31.48% | 1.11 | |
 DVAX | 1.82B | 15.50 | 77.50 | 19.36% | -13.13% | -8.13% | 0.43 | |
 VALN | 462.92M | 5.38 | -3.54 | 3% | -88.3% | -106.21% | 1.95 | |
 IBRX | 7.71B | 7.36 | -19.37 | 6.68% | -6.06% |
Compare NVAX vs Peers
Novavax, Inc. (NVAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NVAX Income Statement
Novavax, Inc. (NVAX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 31.18M | 34.29M | 18.66M | 22.39M | 197.58M | 1.6B | 556.38M | 682.16M | 1.12B | 596.34M |
Revenue Growth % | 103.06% | 9.98% | -45.57% | 19.97% | 782.53% | 709.26% | -65.2% | 22.61% | 64.69% | -52.48% |
Cost of Goods Sold | 0 | 0 | 113.84M | 0 | 0 | 902.64M | 343.77M | 202.74M | 71.14M | 91.62M |
COGS % of Revenue | - | - | 610.02% | - | - | 56.45% | 61.79% | 29.72% | 6.33% | - |
Gross Profit | 31.18M▲ 0% | 34.29M▲ 10.0% | -95.18M▼ 377.6% | 22.39M▲ 123.5% | 197.58M▲ 782.5% | 696.31M▲ 252.4% | 212.61M▼ 69.5% | 479.42M▲ 125.5% | 1.05B▲ 119.5% | 504.72M▲ 0% |
Gross Margin % | 100% | 100% | -510.02% | 100% | 100% | 43.55% | 38.21% | 70.28% | 93.67% | 84.64% |
Gross Profit Growth % | 114.01% | 9.98% | -377.59% | 123.52% | 782.53% | 252.42% | -69.47% | 125.49% | 119.5% | - |
Operating Expenses | 202.89M | 208.21M | 148.26M | 439.11M | 1.88B | 1.34B | 779.13M | 728.35M | 489.07M | 571.48M |
OpEx % of Revenue | 650.78% | 607.23% | 794.44% | 1961.35% | 953.61% | 83.87% | 140.03% | 106.77% | 43.53% | - |
Selling, General & Admin | 34.45M | 34.41M | 34.42M | 145.29M | 298.36M | 488.69M | 468.95M | 337.19M | 150.35M | 127.98M |
SG&A % of Revenue | 110.5% | 100.35% | 184.42% | 648.96% | 151.01% | 30.56% | 84.28% | 49.43% | 13.38% | - |
Research & Development | 168.44M | 173.8M | 113.84M | 747.03M | 2.53B | 1.24B | 737.5M | 391.17M | 336.82M | 345.36M |
R&D % of Revenue | 540.27% | 506.87% | 610.02% | 3336.73% | 1282.77% | 77.26% | 132.55% | 57.34% | 29.98% | - |
Other Operating Expenses | 67K | 108K | -13K | -453.21M | -948.71M | -382.92M | -427.32M | 0 | 1.9M | 2M |
Operating Income | -171.71M▲ 0% | -173.92M▼ 1.3% | -120.58M▲ 30.7% | -416.72M▼ 245.6% | -1.69B▼ 304.7% | -644.74M▲ 61.8% | -566.51M▲ 12.1% | -248.93M▲ 56.1% | 563.27M▲ 326.3% | -66.76M▲ 0% |
Operating Margin % | -550.78% | -507.23% | -646.13% | -1861.35% | -853.61% | -40.32% | -101.82% | -36.49% | 50.14% | -11.19% |
Operating Income Growth % | 36.19% | -1.29% | 30.67% | -245.59% | -304.73% | 61.77% | 12.13% | 56.06% | 326.28% | - |
EBITDA | -161.89M | -165.76M | -114.78M | -411.83M | -1.67B | -615.68M | -525.29M | -200.44M | 590.88M | -47.48M |
EBITDA Margin % | -519.29% | -483.43% | -615.05% | -1839.53% | -847.2% | -38.51% | -94.41% | -29.38% | 52.59% | -7.96% |
EBITDA Growth % | 37.88% | -2.39% | 30.75% | -258.8% | -306.45% | 63.22% | 14.68% | 61.84% | 394.8% | -110.41% |
D&A (Non-Cash Add-back) | 9.82M | 8.16M | 5.8M | 4.88M | 12.66M | 29.05M | 41.23M | 48.5M | 27.61M | 19.27M |
EBIT | -169.7M | -172.56M | -119.08M | -403.11M | -1.69B | -633.77M | -528.62M | -156.54M | 464.71M | -76.28M |
Net Interest Income | -14.07M | -13.61M | -12.1M | -15.14M | -21.13M | -19.88M | -14.42M | -20.07M | -22.55M | -11.92M |
Interest Income | 0 | 0 | 1.51M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 14.07M | 12.19M | 13.61M | 15.14M | 21.13M | 19.88M | 14.42M | 20.07M | 22.55M | 11.92M |
Other Income/Expense | -12.06M | -10.83M | -12.11M | -1.54M | -27.96M | -8.91M | 23.48M | 72.32M | -121.1M | -19.43M |
Pretax Income | -183.77M▲ 0% | -184.75M▼ 0.5% | -132.69M▲ 28.2% | -418.26M▼ 215.2% | -1.71B▼ 309.9% | -653.65M▲ 61.9% | -543.03M▲ 16.9% | -176.62M▲ 67.5% | 442.17M▲ 350.4% | -86.19M▲ 0% |
Pretax Margin % | -589.46% | -538.81% | -711.04% | -1868.23% | -867.76% | -40.88% | -97.6% | -25.89% | 39.36% | -14.45% |
Income Tax | 0 | 1.36M | 0 | 0 | 29.21M | 4.29M | 2.03M | 10.88M | 1.86M | 1.65M |
Effective Tax Rate % | 0% | -0.74% | 0% | 0% | -1.7% | -0.66% | -0.37% | -6.16% | 0.42% | -1.91% |
Net Income | -183.77M▲ 0% | -184.75M▼ 0.5% | -130.1M▲ 29.6% | -418.26M▼ 221.5% | -1.74B▼ 316.9% | -657.94M▲ 62.3% | -545.06M▲ 17.2% | -187.5M▲ 65.6% | 440.3M▲ 334.8% | -87.83M▲ 0% |
Net Margin % | -589.46% | -538.81% | -697.15% | -1868.23% | -882.55% | -41.15% | -97.97% | -27.49% | 39.19% | -14.73% |
Net Income Growth % | 34.36% | -0.53% | 29.58% | -221.49% | -316.91% | 62.27% | 17.16% | 65.6% | 334.83% | -118.35% |
Net Income (Continuing) | -183.77M | -184.75M | -132.69M | -418.26M | -1.74B | -657.94M | -545.06M | -187.5M | 440.3M | -87.83M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -12.56▲ 0% | -9.99▲ 20.5% | -5.40▲ 45.9% | -7.43▼ 37.6% | -23.44▼ 215.5% | -8.42▲ 64.1% | -5.41▲ 35.7% | -1.23▲ 77.3% | 2.54▲ 306.5% | -0.54▲ 0% |
EPS Growth % | 39.27% | 20.46% | 45.95% | -37.59% | -215.48% | 64.08% | 35.75% | 77.26% | 306.5% | -122.64% |
EPS (Basic) | -12.56 | -9.99 | -5.40 | -7.43 | -23.44 | -8.42 | -5.41 | -1.23 | 2.72 | - |
Diluted Shares Outstanding | 14.63M | 18.49M | 24.1M | 57.55M | 74.4M | 78.18M | 100.77M | 152.19M | 173.1M | 163.28M |
Basic Shares Outstanding | 14.63M | 18.49M | 24.1M | 57.55M | 74.4M | 78.18M | 100.77M | 152.19M | 161.99M | 163.28M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NVAX Balance Sheet
Novavax, Inc. (NVAX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 203.31M | 119.28M | 97.25M | 1.25B | 2.16B | 1.7B | 1.14B | 1.13B | 978.28M | 850.82M |
Cash & Short-Term Investments | 106.31M | 70.15M | 78.82M | 711.05M | 1.52B | 1.34B | 568.5M | 923.12M | 735.08M | 790.33M |
Cash Only | 106.31M | 70.15M | 78.82M | 553.4M | 1.52B | 1.34B | 568.5M | 530.23M | 240.63M | 228.36M |
Short-Term Investments | 0 | 0 | 0 | 157.65M | 0 | 0 | 0 | 392.89M | 494.45M | 561.97M |
Accounts Receivable | 0 | 0 | 7.5M | 262.01M | 454.99M | 82.38M | 297.24M | 108.28M | 106.45M | 23.31M |
Days Sales Outstanding | - | - | 146.69 | 4.27K | 840.53 | 18.8 | 195 | 57.94 | 34.58 | 59.73 |
Inventory | 13.09M | 11.97M | 0 | 0 | 0 | 36.68M | 41.7M | 8.75M | 11.54M | 11.46M |
Days Inventory Outstanding | - | - | - | - | - | 14.83 | 44.27 | 15.75 | 59.23 | 46.57 |
Other Current Assets | 19.84M | 3.19M | 7.32M | 103.54M | 56.11M | 86.68M | 166.15M | 32.51M | 125.2M | 25.71M |
Total Non-Current Assets | 99.18M | 88.7M | 75.71M | 334.28M | 421.63M | 555.29M | 653.6M | 431.48M | 198.24M | 192.35M |
Property, Plant & Equipment | 35.99M | 28.43M | 11.45M | 179.95M | 228.7M | 400.49M | 490.99M | 300M | 67.7M | 63.51M |
Fixed Asset Turnover | 0.87x | 1.21x | 1.63x | 0.12x | 0.86x | 3.99x | 1.13x | 2.27x | 16.60x | 4.90x |
Goodwill | 53.56M | 51.97M | 51.15M | 135.38M | 131.48M | 126.33M | 127.45M | 107.48M | 113.46M | 112.89M |
Intangible Assets | 7.87M | 6.54M | 5.58M | 5.72M | 4.77M | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 890K | 958K | 410K | 0 | 1.65M | 1.66M | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 1.76M | 1.77M | 7.53M | 13.22M | 56.69M | 28.47M | 35.16M | 24M | 17.08M | 15.95M |
Total Assets | 302.49M▲ 0% | 207.98M▼ 31.2% | 172.96M▼ 16.8% | 1.58B▲ 815.0% | 2.58B▲ 62.8% | 2.26B▼ 12.3% | 1.8B▼ 20.4% | 1.56B▼ 13.2% | 1.18B▼ 24.6% | 1.04B▲ 0% |
Asset Turnover | 0.10x | 0.16x | 0.11x | 0.01x | 0.08x | 0.71x | 0.31x | 0.44x | 0.95x | 0.50x |
Asset Growth % | -23.28% | -31.25% | -16.84% | 814.96% | 62.83% | -12.34% | -20.42% | -13.19% | -24.6% | -101.53% |
Total Current Liabilities | 73.67M | 45.54M | 25.8M | 579.67M | 2.39B | 2.46B | 1.64B | 1.15B | 459.95M | 342.46M |
Accounts Payable | 5.61M | 9.3M | 2.91M | 54.33M | 127.05M | 216.52M | 132.61M | 41.58M | 24.58M | 16.1M |
Days Payables Outstanding | - | - | 9.33 | - | - | 87.55 | 140.8 | 74.86 | 126.1 | 106.07 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 324.88M | 0 | 0 | 2.51M | 2.11M |
Deferred Revenue (Current) | 25.63M | 10.01M | 1.68M | 273.23M | 1.42B | 370.14M | 241.31M | 675.07M | 140.05M | 446.84M |
Other Current Liabilities | 31.25M | 16.6M | 12.44M | 29.61M | 74.48M | 982.62M | 917.36M | 279.95M | 292.81M | 235.48M |
Current Ratio | 2.76x | 2.62x | 3.77x | 2.15x | 0.90x | 0.69x | 0.70x | 0.98x | 2.13x | 2.48x |
Quick Ratio | 2.58x | 2.36x | 3.77x | 2.15x | 0.90x | 0.68x | 0.67x | 0.97x | 2.10x | 2.45x |
Cash Conversion Cycle | - | - | - | - | - | -53.92 | 98.47 | -1.17 | -32.29 | 0.22 |
Total Non-Current Liabilities | 330.55M | 330.37M | 333.18M | 375.6M | 538.11M | 432.81M | 879.28M | 1.03B | 844.32M | 845.46M |
Long-Term Debt | 317.76M | 319.19M | 320.61M | 322.04M | 323.46M | 166.47M | 168.02M | 169.68M | 246.3M | 292.95M |
Capital Lease Obligations | 0 | 0 | 0 | 40.08M | 0 | 31.24M | 55.92M | 53.73M | 0 | 54.64M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 10.29M | 8.69M | 10.07M | 13.48M | 42.12M | 55.7M | 33.13M | 359.61M | 598.01M | 552.52M |
Total Liabilities | 404.23M | 375.91M | 358.97M | 955.27M | 2.93B | 2.89B | 2.51B | 2.18B | 1.3B | 1.19B |
Total Debt | 317.76M | 319.19M | 321.87M | 467.98M | 453.99M | 549.78M | 229.08M | 230.42M | 248.81M | 295.06M |
Net Debt | 211.46M | 249.03M | 243.05M | -85.42M | -1.06B | -787.1M | -339.42M | -299.81M | 8.18M | 66.69M |
Debt / Equity | - | - | - | 0.75x | - | - | - | - | - | -2.04x |
Debt / EBITDA | - | - | - | - | - | - | - | - | 0.42x | -6.21x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.01x | -1.40x |
Interest Coverage | -12.06x | -14.16x | -8.75x | -26.62x | -80.15x | -31.88x | -36.67x | -7.80x | 20.61x | -6.40x |
Total Equity | -101.73M▲ 0% | -167.94M▼ 65.1% | -186.02M▼ 10.8% | 627.21M▲ 437.2% | -351.67M▼ 156.1% | -634.08M▼ 80.3% | -716.93M▼ 13.1% | -623.84M▲ 13.0% | -127.75M▲ 79.5% | -144.76M▲ 0% |
Equity Growth % | -1734.33% | -65.08% | -10.77% | 437.18% | -156.07% | -80.3% | -13.07% | 12.98% | 79.52% | 167.1% |
Book Value per Share | -6.95 | -9.08 | -7.72 | 10.90 | -4.73 | -8.11 | -7.11 | -4.10 | -0.74 | -0.89 |
Total Shareholders' Equity | -101.73M | -167.94M | -186.02M | 627.21M | -351.67M | -634.08M | -716.93M | -623.84M | -127.75M | -144.76M |
Common Stock | 3.24M | 3.85M | 324K | 714K | 764K | 868K | 1.41M | 1.62M | 1.65M | 1.68M |
Retained Earnings | -1.11B | -1.3B | -1.43B | -1.87B | -3.62B | -4.28B | -4.82B | -5.01B | -4.57B | -4.58B |
Treasury Stock | -2.45M | -2.45M | -2.58M | -41.81M | -85.1M | -90.66M | -92.27M | -95.85M | -103.02M | 0 |
Accumulated OCI | -8.62M | -11.19M | -12.51M | 7.02M | -1.35M | -6.38M | 2.72M | -22.56M | 2.01M | -5.07M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NVAX Cash Flow Statement
Novavax, Inc. (NVAX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -138.7M | -184.82M | -136.62M | -42.54M | 322.95M | -415.94M | -713.97M | -87.26M | -244.63M | -91.56M |
Operating CF Margin % | -444.88% | -539.04% | -732.09% | -190.02% | 163.45% | -26.01% | -128.32% | -12.79% | -21.77% | - |
Operating CF Growth % | 45.71% | -33.26% | 26.08% | 68.86% | 859.14% | -228.79% | -71.65% | 87.78% | -180.34% | 193.61% |
Net Income | -183.77M | -184.75M | -132.69M | -418.26M | -1.74B | -657.94M | -545.06M | -187.5M | 440.3M | -87.83M |
Depreciation & Amortization | 9.82M | 8.16M | 5.68M | 4.88M | 12.66M | 29.05M | 41.23M | 48.5M | 27.61M | 22.34M |
Stock-Based Compensation | 19.81M | 18.31M | 17.05M | 128.03M | 183.63M | 130.3M | 85.36M | 48.15M | 36.02M | 25.73M |
Deferred Taxes | 269K | -55K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 6.07M | -5.35M | -2.63M | 230.78M | 136.79M | 443.8M | 81.35M | -44.89M | 139.14M | 121.33M |
Working Capital Changes | 9.11M | -21.14M | -24.02M | 12.02M | 1.73B | -361.15M | -376.84M | 48.48M | -887.71M | -173.12M |
Change in Receivables | 0 | 1.21M | -4.2M | -422.69M | -192.26M | 249.17M | -274.44M | 354.09M | 61.04M | 73.42M |
Change in Inventory | 0 | 0 | 0 | 0 | -600.33M | -477.8M | -74.46M | 12.91M | -3.24M | -5.84M |
Change in Payables | 5.19M | -6.74M | 0 | 163.16M | 600.33M | 913.4M | -378.81M | -385.63M | -322.57M | -170.8M |
Cash from Investing | 35.97M | 28.6M | 38.49M | -377.78M | 100.15M | -92.98M | -58.81M | -204.04M | -78.27M | -33.31M |
Capital Expenditures | -4.19M | -1.37M | -1.86M | -54.62M | -57.49M | -92.98M | -58.81M | -14.64M | -5.56M | -5.61M |
CapEx % of Revenue | 13.44% | 4% | 9.95% | 243.98% | 29.09% | 5.82% | 10.57% | 2.15% | 0.49% | 0.94% |
Acquisitions | 4.19M | 1.37M | 0 | -165.52M | 57.49M | 0 | 0 | 192.64M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -4.19M | -1.37M | 18.33M | 0 | -57.49M | 0 | 0 | 0 | 18.82M | 58.95M |
Cash from Financing | 64.54M | 102.81M | 98.38M | 984.76M | 461.71M | 324.99M | 4.47M | 260.58M | 27.74M | 72.47M |
Debt Issued (Net) | -37K | 0 | 0 | -96.06M | -127.91M | 81.66M | -352.35M | -3.99M | 32.53M | 80.57M |
Equity Issued (Net) | 63.42M | 100.06M | 97.39M | 1.08B | 564.86M | 249.23M | 360.4M | 263.27M | -4.8M | -8.1M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.8M | -8.1M |
Other Financing | 1.15M | 2.75M | 992K | 5.38M | 24.76M | -5.9M | -3.59M | 1.3M | 0 | 0 |
Net Change in Cash | -38.05M▲ 0% | -53.47M▼ 40.5% | 221K▲ 100.4% | 566.56M▲ 256261.1% | 879.52M▲ 55.2% | -179.41M▼ 120.4% | -765.03M▼ 326.4% | -38.52M▲ 95.0% | -289.24M▼ 650.9% | -45.6M▲ 0% |
Free Cash Flow | -142.88M▲ 0% | -186.2M▼ 30.3% | -138.48M▲ 25.6% | -97.16M▲ 29.8% | 265.46M▲ 373.2% | -508.92M▼ 291.7% | -772.77M▼ 51.8% | -100.32M▲ 87.0% | -250.19M▼ 149.4% | -97.17M▲ 0% |
FCF Margin % | -458.32% | -543.04% | -742.04% | -434% | 134.35% | -31.83% | -138.89% | -14.71% | -22.27% | -16.29% |
FCF Growth % | 47.79% | -30.31% | 25.63% | 29.84% | 373.21% | -291.71% | -51.85% | 87.02% | -149.4% | 50.97% |
FCF per Share | -9.76 | -10.07 | -5.75 | -1.69 | 3.57 | -6.51 | -7.67 | -0.66 | -1.45 | -0.60 |
FCF Conversion (FCF/Net Income) | 0.75x | 1.00x | 1.05x | 0.10x | -0.19x | 0.63x | 1.31x | 0.47x | -0.56x | 1.11x |
Interest Paid | 0 | 0 | 12.19M | 13.71M | 19.43M | 18.04M | 17.35M | 17.57M | 0 | 7.01M |
Taxes Paid | 0 | 0 | 0 | 0 | 12.61M | 17.98M | 190K | 949K | 0 | 3.42M |
NVAX Key Ratios
Novavax, Inc. (NVAX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | - | -189.6% | -1265.72% | - | - | - | - | 89.73% |
Return on Invested Capital (ROIC) | -93.27% | -136.71% | -130.94% | -104.38% | - | - | - | - | - | 55.81% |
Gross Margin | 100% | 100% | -510.02% | 100% | 100% | 43.55% | 38.21% | 70.28% | 93.67% | 84.64% |
Net Margin | -589.46% | -538.81% | -697.15% | -1868.23% | -882.55% | -41.15% | -97.97% | -27.49% | 39.19% | -14.73% |
Debt / Equity | - | - | - | 0.75x | - | - | - | - | - | -2.04x |
Interest Coverage | -12.06x | -14.16x | -8.75x | -26.62x | -80.15x | -31.88x | -36.67x | -7.80x | 20.61x | -6.40x |
FCF Conversion | 0.75x | 1.00x | 1.05x | 0.10x | -0.19x | 0.63x | 1.31x | 0.47x | -0.56x | 1.11x |
Revenue Growth | 103.06% | 9.98% | -45.57% | 19.97% | 782.53% | 709.26% | -65.2% | 22.61% | 64.69% | -52.48% |
Related:NVAX Dividend History·NVAX Revenue History·NVAX Price History·NVAX P/E History·NVAX Financial Ratios·NVAX Institutional Holders
NVAX SEC Filings & Documents
Novavax, Inc. (NVAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
NVAX Frequently Asked Questions
Novavax, Inc. (NVAX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Novavax, Inc. (NVAX) reported $596.3M in revenue for fiscal year 2025. This represents a 596238% increase from $0.1M in 1996.
Novavax, Inc. (NVAX) grew revenue by 64.7% over the past year. This is strong growth.
Novavax, Inc. (NVAX) reported a net loss of $87.8M for fiscal year 2025.
Dividend & Returns
Novavax, Inc. (NVAX) had negative free cash flow of $97.2M in fiscal year 2025, likely due to heavy capital investments.